Janux Therapeutics, Inc.

NASDAQ (USD): Janux Therapeutics, Inc. (JANX)

Last Price

41.26

Today's Change

-2.45 (5.60%)

Day's Change

41.23 - 45.00

Trading Volume

868,184

Overview

Market Cap

2 Billion

Shares Outstanding

52 Million

Avg Volume

569,935

Avg Price (50 Days)

42.09

Avg Price (200 Days)

32.76

PE Ratio

-46.89

EPS

-0.88

Earnings Announcement

05-Nov-2024

Previous Close

43.71

Open

44.68

Day's Range

41.23 - 45.0

Year Range

5.65 - 65.6

Trading Volume

868,184

Price Change Highlight

1 Day Change

-5.61%

5 Day Change

-12.25%

1 Month Change

16.92%

3 Month Change

-6.57%

6 Month Change

1.60%

Ytd Change

274.41%

1 Year Change

287.05%

3 Year Change

39.49%

5 Year Change

64.06%

10 Year Change

64.06%

Max Change

64.06%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment